Adherium (ASK:ADR) today launched over-the-counter sales of its Hailie digital inhaler add-on in the U.S.
The sensor is designed to integrate directly with prescription inhaler medications, sending adherence reminders and relevant data to a user’s smartphone to assist in managing chronic respiratory conditions like asthma and COPD.
“We’re extremely excited to announce the availability of the full Hailie solution in the U.S.,” CEO Arik Anderson said in prepared remarks. “Individuals and families with asthma and COPD can now access a solution that encompasses the world’s most clinically proven asthma and COPD medication adherence platform, cleverly packaged into the simplest interface.
“Hailie is the culmination of 15 years of accelerating research and development and is focused on the premise that if we are to turn the corner on treating chronic conditions, we have to make managing them second nature. Today, through advances in technology, the power of real-time feedback, and data science we can cross that last mile in achieving better health – putting medicine to work in the proving ground of everyday life.”
“We applaud Adherium’s intent to make disease management easy and smart for all families,” Dr. Andrew Weinstein of Asthma Management Systems added. “By leveraging smarter and easier technologies, we see the potential to better help families manage their health, which in turn could produce tremendous results for communities.”
Adherium also said today that it launched an online portal for healthcare professionals to access and analyze data collected from its Hailie sensors.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.